Meda on U.S. Aspects of $9.9 Billion Offer By Mylan

Cleary Gottlieb recently advised Meda AB on U.S. antitrust and corporate aspects of Mylan’s recommended offer for Meda shares. The total value of the offer for all Meda shares, including Meda’s net debt, is approximately $9.9 billion.

The offer was announced on February 10, 2016. On July 27, 2016, the Federal Trade Commission cleared the transaction, subject to Mylan agreeing to divest two generic drugs. That satisfied the final regulatory clearance required to complete the offer.

Meda AB is a global pharmaceutical company headquartered in Sweden, and Mylan N.V. is a global generic and specialty pharmaceuticals company headquartered in the UK.